Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines

The yellow fever 17D virus as a platform for new live attenuated vaccines

“…39 These recombinant live attenuated chimeric viruses have been tested in man to different extents, and due to the inexistence of any alternative, particular attention has been devoted to the immunogenicity and safety of the YF17D-DV tetravalent vaccine. [40][41][42][43][44][45][46] The live attenuated chimeric 17D-DEN tetravalent vaccine candidate from Sanofi-Pasteur constitutes the most tested dengue vaccine possibility. The chimeric viruses proved to be genetically and phenotypically stable, 47 less virulent when compared with the yellow fever vaccine 17D and unable to infect mosquitoes orally.…”

Development of Sanofi Pasteur tetravalent dengue vaccine

“…Phase I and II clinical trials with a 3-dose vaccination regimen over 12 months demonstrate that this candidate vaccine elicits neutralizing antibodies against all four serotypes in both children and adults with a good safety profile 13,16,17 .…”

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

“…[6][7][8] The investigational, YF-17D-based, recombinant, live, attenuated tetravalent dengue vaccine being developed by Sanofi Pasteur (CYD-TDV), 9,10 is one of several dengue vaccines in development 11,12 and has demonstrated satisfactory safety and immunogenicity, and protective efficacy for 3 of the 4 serotypes. [13][14][15][16][17][18] We have previously shown that CYD-TDV vaccination in adults induces significant CD8 + T-cell responses against the YF-17D backbone of the CYD vaccine viruses and T helper 1 (Th1) responses to each dengue serotype without inducing changes in serum pro-inflammatory cytokines. 19 Here we expand on these investigations and report on cellular responses up to one year after CYD-TDV vaccination of a cohort of adolescents and adults recruited in a dengue low endemic area.…”